HYP 2A
Alternative Names: HY-0002; HYP-2ALatest Information Update: 30 Jun 2023
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 27 Apr 2023 Sichuan Huiyu Pharmaceutical announces intention to submit IND to C FDA for Solid tumours in 2023
- 14 Apr 2023 Preclinical trials in Solid tumours in China (PO) before April 2023
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)